<!DOCTYPE HTML>
<!--
	Massively by HTML5 UP
	html5up.net | @ajlkn
	Free for personal and commercial use under the CCA 3.0 license (html5up.net/license)
-->
<html>
	<head>
		<title>My Portfolio</title>
		<meta charset="utf-8" />
		<meta name="viewport" content="width=device-width, initial-scale=1, user-scalable=no" />
		<link rel="stylesheet" href="assets/css/main.css" />
		<noscript><link rel="stylesheet" href="assets/css/noscript.css" /></noscript>
	</head>
	<body class="is-preload">

		<!-- Wrapper -->
			<div id="wrapper" class="fade-in">

				<!-- Intro -->
					<div id="intro">
						<h1>My Portfolio</h1>
						<h3>Research Methods and Professional Practice</h3>
						<ul class="actions">
							<li><a href="#header" class="button icon solid solo fa-arrow-down scrolly">Continue</a></li>
						</ul>
					</div>

				<!-- Nav -->
					<nav id="nav">
						<ul class="icons">
							<li><a href="https://github.com/pmatkowska94/e-portfolio.pmatkowska" class="icon brands fa-github"><span class="label">GitHub</span></a></li>
						</ul>
					</nav>

				<!-- Main -->
					<div id="main">

						<!-- Featured Post -->
							<article class="post featured">
								<header class="major">
									<h2>Literature Review</h2>
									<p>Outline</p>
								</header>
								<img src="images/RM_lit_rev.jpg" alt="" style="width: 100%; height: auto; max-width: 100%;" /> 
                
<h2>Literature Review Outline: Implementing Machine Learning Techniques in Medication Safety Analysis</h2>

<h3>1. What is the focus and aim of your review? Who is your audience?</h3>
<p>
  The focus of this review is to explore how machine learning (ML) techniques are being applied to enhance medication safety analysis. Specifically, it examines the use of ML in the prediction of adverse drug reactions (ADRs), drug-drug interactions (DDIs), and toxicity, as well as its integration into pharmacovigilance systems.
</p>
<p>
  The aim is to synthesise existing research to evaluate ML's potential in improving patient safety, while also identifying ongoing challenges and future directions.
</p>
<p>
  The target audience includes academic researchers, data scientists, and professionals in the fields of pharmacology, individuals with foundational or advanced knowledge in ML and medication safety.
</p>

<h3>2. Why is there a need for your review? Why is it significant?</h3>
<p>
  The need for this review stems from the rapid expansion of data in the pharmaceutical industry and the increasing interest in applying ML to manage this complexity. Medication safety remains one of the most pressing challenges, with high failure rates in drug development, underreported ADRs, and limited predictive capabilities of traditional tools.
</p>
<p>
  This review is significant because it highlights how ML-driven innovations can enhance pharmacovigilance, reduce failure rates, and ultimately improve patient outcomes, addressing a critical issue in healthcare and drug development.
</p>

<h3>3. What is the context of the topic or issue? What perspective do you take? What framework do you use to synthesise the literature?</h3>
<p>
  The review is set within the context of Pharma 4.0, where digital transformation and big data are reshaping pharmaceutical research and regulation. Medication safety is a key concern given the complexity of drug interactions and patient variability.
</p>
<p>
  The review adopts a technology-optimistic but critical perspective, recognising both the opportunities and the limitations of ML in this domain.
</p>
<p>
  To synthesise the literature, a thematic framework was used, organised around key application areas of ML: ADR prediction, DDI detection, toxicity analysis, pharmacovigilance systems, and broader implementation challenges (data quality, interpretability, and ethics).
</p>

<h3>4. How did you locate and select sources for inclusion in the review?</h3>
<p>
  Sources were selected through a combination of keyword-based searches in scientific databases (e.g., PubMed, ScienceDirect, Google Scholar) using terms such as machine learning, adverse drug reaction prediction, pharmacovigilance, toxicity modelling, and drug safety.
</p>
<p>
  Studies were chosen based on their relevance to the pharmaceutical domain, focus on ML applications, and scientific credibility. Emphasis was placed on recent research (2016–2025) to reflect current developments in the field.
</p>

<h3>5. How is the review structured?</h3>
<ul>
  <li><strong>Introduction</strong> – Establishes the problem, significance, and scope.</li>
  <li><strong>Literature Review</strong> – Organised into key themes:
    <ul>
      <li>ADR and AE Prediction</li>
      <li>ML-Based Approaches</li>
      <li>ML in Pharmacovigilance Systems</li>
      <li>DDI Prediction</li>
      <li>Toxicity Prediction</li>
    </ul>
  </li>
  <li><strong>Challenges and Ongoing Research</strong> – Covers data issues, interpretability, regulation, and ethical concerns.</li>
  <li><strong>Summary/conclusions and future directions</strong></li>
</ul>

<h3>6. What are the main findings in the literature on this topic?</h3>
<ul>
  <li>ML significantly improves the early detection and prediction of ADRs, DDIs, and toxicity, surpassing traditional approaches.</li>
  <li>ML models offer robust predictive performance when trained on rich datasets such as EHRs and FAERS.</li>
  <li>ML enhances efficiency and scalability in pharmacovigilance.</li>
  <li>Despite its promise, challenges remain in data quality, model transparency, and regulatory integration.</li>
</ul>

<h3>7. What are the main strengths and limitations of this literature?</h3>

<h4>Strengths:</h4>
<ul>
  <li>The literature includes a wide range of high-quality, peer-reviewed studies published in reputable journals, as well as reports from regulatory bodies like the FDA, providing both academic and practical perspectives.</li>
  <li>Many of the sources are published within the last 5–7 years, capturing the most up-to-date applications of ML in the pharmaceutical context.</li>
  <li>The literature draws from multiple disciplines, including pharmacology, computer science, data science, chemistry and bioinformatics, which enriches the understanding of how ML contributes to medication safety.</li>
  <li>Many studies demonstrate the application of ML using real-world datasets such as EHRs, FAERS, or toxicogenomic data, reflecting practical relevance.</li>
</ul>

<h4>Limitations:</h4>
<ul>
  <li>The reviewed studies often differ in outcome metrics and validation methods, making cross-study comparisons difficult.</li>
  <li>Some papers do not provide sufficient detail on data preprocessing, feature selection, or model evaluation criteria.</li>
  <li>Studies rely on specific institutional or geographic datasets, which may introduce selection bias.</li>
  <li>Some literature focuses heavily on algorithmic performance (e.g., accuracy, AUC) without fully addressing practical implementation barriers, such as clinical integration or regulatory acceptability.</li>
</ul>

<h3>8. Are there any discrepancies in this literature?</h3>
<ul>
  <li><strong>Performance outcomes:</strong> Some studies report high accuracy, while others find inconsistent results due to small or biased datasets.</li>
  <li><strong>Interpretability approaches:</strong> Not all studies employ methods to make predictions explainable, leading to debate over clinical usefulness.</li>
  <li><strong>Regulatory viewpoints:</strong> While some regulators (e.g., FDA) experiment with ML, widespread adoption is limited due to trust and compliance issues.</li>
</ul>

<h3>9. What conclusions do you draw from the review? What do you argue needs to be done as an outcome of the review?</h3>
<p>
  ML holds strong potential to revolutionise medication safety analysis by enabling earlier, faster, and more accurate identification of risks. It supports more efficient drug development and regulatory surveillance. However, its effectiveness is constrained by data quality issues, interpretability challenges, and lack of standardisation.
</p>

             
                <ul class="actions special">
										<li><a href="index.html" class="button">Home</a></li>
									</ul>
                
							</article>

					</div>

				<!-- Footer -->
					<footer id="footer">
					</footer>

				<!-- Copyright -->
					<div id="copyright">
						<ul><li>&copy; </li><li>Design: <a href="https://html5up.net">HTML5 UP</a></li></ul>
					</div>

			</div>

		<!-- Scripts -->
			<script src="assets/js/jquery.min.js"></script>
			<script src="assets/js/jquery.scrollex.min.js"></script>
			<script src="assets/js/jquery.scrolly.min.js"></script>
			<script src="assets/js/browser.min.js"></script>
			<script src="assets/js/breakpoints.min.js"></script>
			<script src="assets/js/util.js"></script>
			<script src="assets/js/main.js"></script>

	</body>
</html>
